Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients.

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY OncoTargets and therapy Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S478613

Imjai Chitapanarux, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Narongchai Autsavapromporn, Tapanut Ariyanon, Junji Akagi, Akira Mizoo

{"title":"Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients.","authors":"Imjai Chitapanarux, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Narongchai Autsavapromporn, Tapanut Ariyanon, Junji Akagi, Akira Mizoo","doi":"10.2147/OTT.S478613","DOIUrl":null,"url":null,"abstract":"Purpose: Hydrogen (H2) gas inhalation might alleviate acute radiotherapy toxicities by scavenging free radicals produced by ionizing radiation and anti-inflammatory properties. This study aimed to investigate the feasibility and safety of H2 gas inhalation during concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck cancer (LAHNC).Patients and methods: We designed a pilot prospective study combining CCRT with aerosol inhalation of H2 gas. Each patient was scheduled to receive daily intensity-modulated radiotherapy (IMRT) in 33 fractions on a weekday and six cycles of weekly chemotherapy. All patients inhaled H2 gas through a cannula or mask 1 hour per day, 1-2 hours before IMRT. The primary endpoint was the feasibility of H2 inhalation. Eighty percent of the patients who completed at least 20 applications of H2 gas inhalation were considered feasible. The secondary endpoints were safety profiles during H2 gas inhalation (vital signs and symptoms related to H2 gas inhalation) and acute toxicities during CCRT.Results: We enrolled 10 patients with LAHNC between July 2023 and December 2023. All patients received 33 fractions of H2 gas inhalation on the same day as the IMRT. Vital signs during and at the end of H2 gas inhalation were stable in all patients. None of the 10 patients had hypertension or hypotension during any of the 33 inhalations. No adverse events related to H2 gas inhalation, such as cough, nasal bleeding, dizziness, headache, nausea, or vomiting, were reported. Grade 3 leukopenia was found in two patients (20%) during the 5th week of CCRT. Grade 2 radiation dermatitis and pharyngitis were found in three patients (30%).Conclusion: H2 gas inhalation combined with CCRT is feasible and safe for patients with LAHNC.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"863-870"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531231/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S478613","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hydrogen (H₂) gas inhalation might alleviate acute radiotherapy toxicities by scavenging free radicals produced by ionizing radiation and anti-inflammatory properties. This study aimed to investigate the feasibility and safety of H₂ gas inhalation during concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck cancer (LAHNC).

Patients and methods: We designed a pilot prospective study combining CCRT with aerosol inhalation of H₂ gas. Each patient was scheduled to receive daily intensity-modulated radiotherapy (IMRT) in 33 fractions on a weekday and six cycles of weekly chemotherapy. All patients inhaled H₂ gas through a cannula or mask 1 hour per day, 1-2 hours before IMRT. The primary endpoint was the feasibility of H₂ inhalation. Eighty percent of the patients who completed at least 20 applications of H₂ gas inhalation were considered feasible. The secondary endpoints were safety profiles during H₂ gas inhalation (vital signs and symptoms related to H₂ gas inhalation) and acute toxicities during CCRT.

Results: We enrolled 10 patients with LAHNC between July 2023 and December 2023. All patients received 33 fractions of H₂ gas inhalation on the same day as the IMRT. Vital signs during and at the end of H₂ gas inhalation were stable in all patients. None of the 10 patients had hypertension or hypotension during any of the 33 inhalations. No adverse events related to H₂ gas inhalation, such as cough, nasal bleeding, dizziness, headache, nausea, or vomiting, were reported. Grade 3 leukopenia was found in two patients (20%) during the 5th week of CCRT. Grade 2 radiation dermatitis and pharyngitis were found in three patients (30%).

Conclusion: H₂ gas inhalation combined with CCRT is feasible and safe for patients with LAHNC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

局部晚期头颈癌患者吸入氢气的试点可行性和安全性研究

目的：吸入氢气（H2）可清除电离辐射产生的自由基并具有抗炎作用，从而减轻急性放疗毒性。本研究旨在探讨在局部晚期头颈癌（LAHNC）患者接受同步放化疗（CCRT）期间吸入氢气的可行性和安全性：我们设计了一项试验性前瞻性研究，将CCRT与吸入H2气体相结合。每位患者都被安排在工作日接受每天33次的调强放射治疗（IMRT）和每周6个周期的化疗。所有患者每天通过插管或面罩吸入 H2 气体 1 小时，时间为 IMRT 开始前 1-2 小时。主要终点是吸入 H2 的可行性。在完成至少 20 次 H2 气体吸入的患者中，有 80% 被认为是可行的。次要终点是吸入 H2 气体期间的安全性概况（与吸入 H2 气体相关的生命体征和症状）和 CCRT 期间的急性毒性：我们在 2023 年 7 月至 2023 年 12 月期间招募了 10 名 LAHNC 患者。所有患者在接受 IMRT 的同一天接受了 33 次 H2 气体吸入治疗。所有患者在吸入 H2 气体期间和结束时的生命体征都很稳定。在 33 次吸入过程中，10 名患者均未出现高血压或低血压。没有出现与吸入 H2 气体有关的不良反应，如咳嗽、鼻出血、头晕、头痛、恶心或呕吐。在 CCRT 第 5 周，两名患者（20%）出现了 3 级白细胞减少症。三名患者（30%）出现了二级放射性皮炎和咽炎：结论：H2气体吸入联合CCRT对LAHNC患者是可行且安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.